cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.26023/13ax-sfwt-290v
title: BB-FLUX: Calculated AirSOF AOD Data. Version 1.0

description: Calculated AODs at 355, 450, and 550 nm for Solar Occultation Flux instrument (CU AirSOF) data collected onboard the University of Wyoming King Air during the 2018 Biomass Burning Fluxes of Trace Gases and Aerosols (BB-FLUX) campaign from 21 July to 15 September 2018. This data set is in ICARTT format. Please see the header portion of the data files for details on instruments, parameters, quality assurance, quality control, contact information, and data set comments.
DOI: 10.6084/m9.figshare.28931765
title: Processed data for the manuscript: A unified picture of structural relaxation, beta relaxation and excess wing in glass formers

description: This dataset contains all processed data for the manuscript titled by "A unified picture of structural relaxation, beta relaxation and excess wing in glass formers".
DOI: 10.6084/m9.figshare.28931765.v2
title: Processed data for the manuscript: A unified picture of structural relaxation, beta relaxation and excess wing in glass formers

description: This dataset contains all processed data for the manuscript titled by "A unified picture of structural relaxation, beta relaxation and excess wing in glass formers".
DOI: 10.6084/m9.figshare.28931765.v3
title: Processed data for the manuscript: A unified picture of structural relaxation, beta relaxation and excess wing in glass formers

description: This dataset contains all processed data for the manuscript titled by "A unified picture of structural relaxation, beta relaxation and excess wing in glass formers".
DOI: 10.25346/s6eecgix/w7b4nz
title: colorTarget.jpg
DOI: 10.25346/s6eecgix/wsfveg
title: msXL_322v_15_06.jpg
DOI: 10.25346/s6eecgix/iv9wll
title: msXL_322v_15_05.jpg
DOI: 10.25346/s6eecgix/5fjwuq
title: msXL_322v_15_04.jpg
DOI: 10.25346/s6eecgix/lkygnn
title: msXL_322v_15_03.jpg
DOI: 10.25346/s6eecgix/tiymo2
title: msXL_322v_15_02.jpg
DOI: 10.25346/s6eecgix/hrczwq
title: msXL_322v_15_01.jpg
DOI: 10.25346/s6eecgix/k7lzk7
title: msXL_322v_0_ring.jpg
DOI: 10.25346/s6eecgix/laqhvv
title: msXL_322v.jpg
DOI: 10.25346/s6eecgix/tyzobi
title: LEGGIMI_IT.txt
DOI: 10.25346/s6eecgix/pp3eb2
title: LCC_day1.tif
DOI: 10.25346/s6eecgix/gklvxw
title: colorTarget.tif
DOI: 10.25346/s6eecgix/wssaff
title: LCC_day1.jpg
DOI: 10.25346/s6eecgix/rrjk7m
title: msXL_323r_31_16.jpg
DOI: 10.25346/s6eecgix/vt7olj
title: msXL_323r_31_15.jpg
DOI: 10.25346/s6eecgix/nrqew3
title: msXL_323r_31_14.jpg
DOI: 10.25346/s6eecgix/kd35ft
title: msXL_323r_31_13.jpg
DOI: 10.25346/s6eecgix/vpf0kt
title: msXL_323r_15_12.jpg
DOI: 10.25346/s6eecgix/9wpask
title: msXL_323r_15_11.jpg
DOI: 10.25346/s6eecgix/qe5fcf
title: msXL_323r_15_10.jpg
DOI: 10.25346/s6eecgix/ppulnf
title: msXL_323r_15_09.jpg
DOI: 10.25346/s6eecgix/6iz4y0
title: msXL_323r_15_08.jpg
DOI: 10.25346/s6eecgix/mhy3jz
title: msXL_323r_15_07.jpg
DOI: 10.26023/yz30-bz3m-fy0z
title: MethaneAIR: Picarro G2401-m WS-CRDS CO2, CH4, CO and H2O in situ mixing ratio observations - ICARTT format. Version 1.0

description: This dataset contains carbon dioxide (CO2), methane (CH4), carbon monoxide (CO) and water vapor (H2O) in situ mixing ratio observations collected by the PICARRO G2401-m aboard the NSF/NCAR GV during the MethaneAIR project.
DOI: 10.25346/s6eecgix/hvjg9e
title: msXL_323r_15_06.jpg
DOI: 10.25346/s6eecgix/utqxeh
title: msXL_323r_15_05.jpg
DOI: 10.25346/s6eecgix/aymaot
title: msXL_323r_15_04.jpg
DOI: 10.25346/s6eecgix/xi9bo9
title: msXL_323r_15_03.jpg
DOI: 10.25346/s6eecgix/0qewci
title: msXL_323r_15_02.jpg
DOI: 10.25346/s6eecgix/f08bkg
title: msXL_323r_15_01.jpg
DOI: 10.25346/s6eecgix/vw3jqs
title: msXL_323r_0_ring.jpg
DOI: 10.25346/s6eecgix/ghjs7e
title: msXL_323r.jpg
DOI: 10.25346/s6eecgix/zislcd
title: msXL_322v_65_43.tif
DOI: 10.25346/s6eecgix/9fp00g
title: msXL_322v_65_42.tif
DOI: 10.25346/s6eecgix/roj9rm
title: msXL_322v_65_41.tif
DOI: 10.25346/s6eecgix/35fvoa
title: msXL_322v_65_40.tif
DOI: 10.25346/s6eecgix/n3pahc
title: msXL_322v_65_39.tif
DOI: 10.25346/s6eecgix/n6gald
title: msXL_322v_65_38.tif
DOI: 10.25346/s6eecgix/vqdy7n
title: msXL_322v_65_37.tif
DOI: 10.25346/s6eecgix/7tvxpo
title: msXL_322v_46_36.tif
DOI: 10.25346/s6eecgix/uz76ih
title: msXL_322v_46_35.tif
DOI: 10.25346/s6eecgix/cxu0jk
title: msXL_322v_46_34.tif
DOI: 10.25346/s6eecgix/fbmpmf
title: msXL_322v_46_33.tif
DOI: 10.25346/s6eecgix/eqpl0s
title: msXL_322v_46_32.tif
DOI: 10.25346/s6eecgix/hcyw2z
title: msXL_322v_46_31.tif
DOI: 10.25346/s6eecgix/befh7r
title: msXL_322v_46_30.tif
DOI: 10.5281/zenodo.17283033
title: A Synergistic, Multidisciplinary Framework for Developing Highly Efficacious, Safe, and Cost-Effective Therapeutics for Progressive Multifocal Leukoencephalopathy (PML) and Other Rare Diseases

description: This paper presents a synergistic, multidisciplinary framework for developing effective therapeutics for Progressive Multifocal Leukoencephalopathy (PML) and other rare diseases. It addresses the significant challenges in this field, such as the Blood-Brain Barrier, small patient populations, and the high failure rate of conventional drug development.

The proposed solution is a dynamic ecosystem integrating 17 scientific, clinical, and social disciplines that work in a feedback-driven loop. Key innovations include AI-driven drug discovery for repurposing compounds, advanced T-cell therapies like DIAVIS which show a 69% survival rate at 12 months, and novel nanoparticle systems designed for superior Blood-Brain Barrier penetration.

The framework also utilizes Bayesian adaptive clinical trials, which are optimized for small patient cohorts, and is designed to be generalizable to other rare conditions. It leverages gene therapies like CRISPR for sickle cell disease and Zolgensma for spinal muscular atrophy as examples of its broader applicability. Supported by mathematical modeling and in silico simulations, the paper provides a 10-year roadmap that projects a 45% reduction in drug development timelines. The overall goal is to create a robust, scalable, and equitable blueprint for accelerating the delivery of novel treatments for rare diseases.
DOI: 10.5281/zenodo.17283034
title: A Synergistic, Multidisciplinary Framework for Developing Highly Efficacious, Safe, and Cost-Effective Therapeutics for Progressive Multifocal Leukoencephalopathy (PML) and Other Rare Diseases

description: This paper presents a synergistic, multidisciplinary framework for developing effective therapeutics for Progressive Multifocal Leukoencephalopathy (PML) and other rare diseases. It addresses the significant challenges in this field, such as the Blood-Brain Barrier, small patient populations, and the high failure rate of conventional drug development.

The proposed solution is a dynamic ecosystem integrating 17 scientific, clinical, and social disciplines that work in a feedback-driven loop. Key innovations include AI-driven drug discovery for repurposing compounds, advanced T-cell therapies like DIAVIS which show a 69% survival rate at 12 months, and novel nanoparticle systems designed for superior Blood-Brain Barrier penetration.

The framework also utilizes Bayesian adaptive clinical trials, which are optimized for small patient cohorts, and is designed to be generalizable to other rare conditions. It leverages gene therapies like CRISPR for sickle cell disease and Zolgensma for spinal muscular atrophy as examples of its broader applicability. Supported by mathematical modeling and in silico simulations, the paper provides a 10-year roadmap that projects a 45% reduction in drug development timelines. The overall goal is to create a robust, scalable, and equitable blueprint for accelerating the delivery of novel treatments for rare diseases.
DOI: 10.25346/s6eecgix/fkyw8o
title: msXL_322v_46_29.tif
DOI: 10.25346/s6eecgix/o4vk5p
title: msXL_322v_46_28.tif
DOI: 10.25346/s6eecgix/ojbd0k
title: msXL_322v_46_27.tif
DOI: 10.25346/s6eecgix/die8vs
title: msXL_322v_46_26.tif
DOI: 10.25346/s6eecgix/jrl89m
title: msXL_322v_31_23.tif
DOI: 10.25346/s6eecgix/129azz
title: msXL_322v_31_22.tif
DOI: 10.25346/s6eecgix/fvy2w4
title: msXL_322v_31_21.tif
DOI: 10.25346/s6eecgix/xpwnnx
title: msXL_322v_31_20.tif
DOI: 10.25346/s6eecgix/0nkzj7
title: msXL_322v_31_19.tif
DOI: 10.25346/s6eecgix/bnijmp
title: msXL_322v_31_18.tif
DOI: 10.25346/s6eecgix/gthb8g
title: msXL_322v_31_17.tif
DOI: 10.25346/s6eecgix/hscpvh
title: msXL_322v_31_16.tif
DOI: 10.25346/s6eecgix/8dvkiv
title: msXL_322v_31_15.tif
DOI: 10.25346/s6eecgix/i1tn3r
title: msXL_322v_31_14.tif
DOI: 10.25346/s6eecgix/83ofrh
title: msXL_322v_31_13.tif
DOI: 10.25346/s6eecgix/qymn3n
title: msXL_322v_15_12.tif
DOI: 10.25346/s6eecgix/jai3b9
title: msXL_322v_15_11.tif
DOI: 10.25346/s6eecgix/secrwo
title: msXL_322v_15_10.tif
DOI: 10.25346/s6eecgix/vbxyrl
title: msXL_322v_15_09.tif
DOI: 10.25346/s6eecgix/q7dngm
title: msXL_322v_15_08.tif
DOI: 10.25346/s6eecgix/ehhiju
title: msXL_322v_15_07.tif
DOI: 10.25346/s6eecgix/nsklzl
title: msXL_322v_15_06.tif
DOI: 10.6084/m9.figshare.30291886.v1
title: Additional file 2 of Genetic underpinnings of the heterogeneous impact of obesity on lipid levels and cardiovascular disease

description: Additional file 2: Supplementary Tables.
DOI: 10.25346/s6eecgix/jiywd4
title: msXL_322v_15_05.tif
DOI: 10.6084/m9.figshare.30291886
title: Additional file 2 of Genetic underpinnings of the heterogeneous impact of obesity on lipid levels and cardiovascular disease

description: Additional file 2: Supplementary Tables.
DOI: 10.25346/s6eecgix/opwuuz
title: msXL_322v_15_04.tif
DOI: 10.25346/s6eecgix/kbgptp
title: msXL_322v_15_03.tif
DOI: 10.25346/s6eecgix/e5dkac
title: msXL_322v_15_02.tif
DOI: 10.25346/s6eecgix/uvuaxm
title: msXL_322v_15_01.tif
DOI: 10.25346/s6eecgix/0m6evf
title: msXL_322v_0_ring.tif
DOI: 10.25346/s6eecgix/yyu46f
title: msXL_322v.tif
DOI: 10.25346/s6eecgix/nslk92
title: plane_8.jpg
DOI: 10.25346/s6eecgix/kfuexy
title: plane_7.jpg
DOI: 10.6084/m9.figshare.30291909
title: Additional file 1 of Computational investigation of the sequence context of arginine/glycine-rich motifs in the human proteome

description: Supplementary Material 1
DOI: 10.25346/s6eecgix/fhdtxn
title: plane_6.jpg
DOI: 10.6084/m9.figshare.30291909.v1
title: Additional file 1 of Computational investigation of the sequence context of arginine/glycine-rich motifs in the human proteome

description: Supplementary Material 1
DOI: 10.6084/m9.figshare.30291912
title: Additional file 2 of Computational investigation of the sequence context of arginine/glycine-rich motifs in the human proteome

description: Supplementary Material 2
DOI: 10.6084/m9.figshare.30291912.v1
title: Additional file 2 of Computational investigation of the sequence context of arginine/glycine-rich motifs in the human proteome

description: Supplementary Material 2
DOI: 10.25346/s6eecgix/v6sgy9
title: plane_5.jpg
DOI: 10.25346/s6eecgix/ekxpqx
title: plane_4.jpg
DOI: 10.25346/s6eecgix/ghjcjf
title: plane_3.jpg
DOI: 10.6084/m9.figshare.30291930
title: Additional file 2 of Analysing the determinants of healthcare insurance uptake in Nigeria

description: Supplementary Material 2.
DOI: 10.6084/m9.figshare.30291930.v1
title: Additional file 2 of Analysing the determinants of healthcare insurance uptake in Nigeria

description: Supplementary Material 2.
DOI: 10.25346/s6eecgix/ga6ocj
title: plane_2.jpg
DOI: 10.25346/s6eecgix/1vbuxe
title: plane_1.jpg
DOI: 10.6084/m9.figshare.30291928
title: Additional file 1 of Global nexus of smoking prevalence, healthcare quality and respiratory cancer mortality: a cross-continental study

description: Supplementary Material 1: S1 Appendix. Data file
DOI: 10.6084/m9.figshare.30291928.v1
title: Additional file 1 of Global nexus of smoking prevalence, healthcare quality and respiratory cancer mortality: a cross-continental study

description: Supplementary Material 1: S1 Appendix. Data file
DOI: 10.25346/s6eecgix/h3xzyx
title: plane_0.jpg
DOI: 10.25346/s6eecgix/2zbqau
title: info.json
DOI: 10.25346/s6eecgix/tr4fwc
title: msXL_322v.relight
DOI: 10.25346/s6eecgix/vg0aav
title: msXL_322v_65_43.jpg
DOI: 10.25346/s6eecgix/hgqble
title: msXL_322v_65_42.jpg
DOI: 10.25346/s6eecgix/qvzqkg
title: msXL_322v_65_41.jpg
DOI: 10.25346/s6eecgix/kaowwj
title: msXL_322v_65_40.jpg
DOI: 10.25346/s6eecgix/j5h0wp
title: msXL_322v_65_39.jpg
DOI: 10.25346/s6eecgix/ef8zea
title: msXL_322v_65_38.jpg
DOI: 10.6084/m9.figshare.30291955
title: Additional file 1 of Pleura-ABCDE - a structured expert-based protocol for neonatal lung ultrasound documentation and interpretation

description: Supplementary Material 1
DOI: 10.6084/m9.figshare.30291955.v1
title: Additional file 1 of Pleura-ABCDE - a structured expert-based protocol for neonatal lung ultrasound documentation and interpretation

description: Supplementary Material 1
DOI: 10.25346/s6eecgix/0jnusp
title: msXL_322v_65_37.jpg
DOI: 10.25346/s6eecgix/5xe9kv
title: msXL_322v_46_36.jpg
DOI: 10.25346/s6eecgix/lgdyiz
title: msXL_322v_46_35.jpg
DOI: 10.25346/s6eecgix/2veo7b
title: msXL_322v_46_34.jpg
DOI: 10.25346/s6eecgix/u5xutw
title: msXL_322v_46_33.jpg
DOI: 10.6084/m9.figshare.30291960
title: Additional file 1 of Genotype-by-genotype interactions reveal transcription patterns underlying resistance responses in Norway spruce to Heterobasidion annosum s.s

description: Supplementary Material 1.
DOI: 10.6084/m9.figshare.30291960.v1
title: Additional file 1 of Genotype-by-genotype interactions reveal transcription patterns underlying resistance responses in Norway spruce to Heterobasidion annosum s.s

description: Supplementary Material 1.
DOI: 10.6084/m9.figshare.30291963
title: Additional file 2 of Genotype-by-genotype interactions reveal transcription patterns underlying resistance responses in Norway spruce to Heterobasidion annosum s.s

description: Supplementary Material 2.
DOI: 10.6084/m9.figshare.30291963.v1
title: Additional file 2 of Genotype-by-genotype interactions reveal transcription patterns underlying resistance responses in Norway spruce to Heterobasidion annosum s.s

description: Supplementary Material 2.
DOI: 10.6084/m9.figshare.30291966
title: Additional file 3 of Genotype-by-genotype interactions reveal transcription patterns underlying resistance responses in Norway spruce to Heterobasidion annosum s.s

description: Supplementary Material 3.
DOI: 10.6084/m9.figshare.30291966.v1
title: Additional file 3 of Genotype-by-genotype interactions reveal transcription patterns underlying resistance responses in Norway spruce to Heterobasidion annosum s.s

description: Supplementary Material 3.
DOI: 10.25346/s6eecgix/59np8n
title: msXL_322v_46_32.jpg
DOI: 10.6084/m9.figshare.30291969
title: Additional file 4 of Genotype-by-genotype interactions reveal transcription patterns underlying resistance responses in Norway spruce to Heterobasidion annosum s.s

description: Supplementary Material 4.
DOI: 10.6084/m9.figshare.30291969.v1
title: Additional file 4 of Genotype-by-genotype interactions reveal transcription patterns underlying resistance responses in Norway spruce to Heterobasidion annosum s.s

description: Supplementary Material 4.
DOI: 10.6084/m9.figshare.30291972
title: Additional file 5 of Genotype-by-genotype interactions reveal transcription patterns underlying resistance responses in Norway spruce to Heterobasidion annosum s.s

description: Supplementary Material 5.
DOI: 10.6084/m9.figshare.30291972.v1
title: Additional file 5 of Genotype-by-genotype interactions reveal transcription patterns underlying resistance responses in Norway spruce to Heterobasidion annosum s.s

description: Supplementary Material 5.
DOI: 10.6084/m9.figshare.30291975
title: Additional file 6 of Genotype-by-genotype interactions reveal transcription patterns underlying resistance responses in Norway spruce to Heterobasidion annosum s.s

description: Supplementary Material 6.
DOI: 10.6084/m9.figshare.30291975.v1
title: Additional file 6 of Genotype-by-genotype interactions reveal transcription patterns underlying resistance responses in Norway spruce to Heterobasidion annosum s.s

description: Supplementary Material 6.
DOI: 10.25346/s6eecgix/pzre8a
title: msXL_322v_46_31.jpg
DOI: 10.25346/s6eecgix/nuqnug
title: msXL_322v_46_30.jpg
DOI: 10.25346/s6eecgix/pkziyv
title: msXL_322v_46_29.jpg
DOI: 10.25346/s6eecgix/pyb9ou
title: msXL_322v_46_28.jpg
DOI: 10.6084/m9.figshare.30291988.v1
title: Additional file 3 of Machine learning-based radiomics using magnetic resonance images for prediction of clinical complete response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer

description: Additional file3 (XLSX 11 KB)
DOI: 10.6084/m9.figshare.30291991
title: Additional file 4 of Machine learning-based radiomics using magnetic resonance images for prediction of clinical complete response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer

description: Additional file4 (XLSX 14 KB)
DOI: 10.6084/m9.figshare.30291991.v1
title: Additional file 4 of Machine learning-based radiomics using magnetic resonance images for prediction of clinical complete response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer

description: Additional file4 (XLSX 14 KB)
DOI: 10.6084/m9.figshare.30291994
title: Additional file 5 of Machine learning-based radiomics using magnetic resonance images for prediction of clinical complete response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer

description: Additional file5 (XLSX 11 KB)
DOI: 10.25346/s6eecgix/jeonib
title: msXL_322v_46_27.jpg
DOI: 10.6084/m9.figshare.30291988
title: Additional file 3 of Machine learning-based radiomics using magnetic resonance images for prediction of clinical complete response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer

description: Additional file3 (XLSX 11 KB)
DOI: 10.6084/m9.figshare.30291994.v1
title: Additional file 5 of Machine learning-based radiomics using magnetic resonance images for prediction of clinical complete response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer

description: Additional file5 (XLSX 11 KB)
DOI: 10.6084/m9.figshare.30291997
title: Additional file 6 of Machine learning-based radiomics using magnetic resonance images for prediction of clinical complete response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer

description: Additional file6 (XLSX 12 KB)
DOI: 10.6084/m9.figshare.30291997.v1
title: Additional file 6 of Machine learning-based radiomics using magnetic resonance images for prediction of clinical complete response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer

description: Additional file6 (XLSX 12 KB)
DOI: 10.25346/s6eecgix/v6hajk
title: msXL_322v_46_26.jpg
DOI: 10.25346/s6eecgix/auqgqw
title: msXL_322v_46_25.jpg
DOI: 10.25346/s6eecgix/11rp36
title: msXL_322v_31_24.jpg
DOI: 10.25346/s6eecgix/uhnj5x
title: msXL_322v_31_23.jpg
DOI: 10.25346/s6eecgix/cifshz
title: msXL_322v_31_22.jpg
DOI: 10.6084/m9.figshare.30292011
title: Additional file 1 of Discovery of small molecules with anthelmintic potential in the Medicines for Malaria Venture’s COVID and Global Health Priority Boxes using an infrared-based assay for Caenorhabditis elegans motility

description: Additional file 1: Additional Table 1. Primary screen activities of the 400 compounds in the MMV COVID and Global Health Priority Boxes. Compounds were tested at 40 µM for modulation of C. elegans motility after 24 h. Relative to DMSO control, the degree to which worm motility was decreased was characterized as a hit if &lt; 25%. One (Global Health Priority Box (GHPB)) or two assays (COVID Box) in triplicate was performed. P-values were calculated using a one-sample t-test for the hit compounds only.
DOI: 10.6084/m9.figshare.30292011.v1
title: Additional file 1 of Discovery of small molecules with anthelmintic potential in the Medicines for Malaria Venture’s COVID and Global Health Priority Boxes using an infrared-based assay for Caenorhabditis elegans motility

description: Additional file 1: Additional Table 1. Primary screen activities of the 400 compounds in the MMV COVID and Global Health Priority Boxes. Compounds were tested at 40 µM for modulation of C. elegans motility after 24 h. Relative to DMSO control, the degree to which worm motility was decreased was characterized as a hit if &lt; 25%. One (Global Health Priority Box (GHPB)) or two assays (COVID Box) in triplicate was performed. P-values were calculated using a one-sample t-test for the hit compounds only.
DOI: 10.25346/s6eecgix/ydgph1
title: msXL_322v_31_21.jpg
DOI: 10.25346/s6eecgix/4xji1n
title: msXL_322v_31_20.jpg
DOI: 10.25346/s6eecgix/nrvvgw
title: msXL_322v_31_19.jpg
DOI: 10.25346/s6eecgix/bih0vk
title: msXL_322v_31_18.jpg
DOI: 10.25346/s6eecgix/guviuy
title: msXL_322v_31_17.jpg
DOI: 10.25346/s6eecgix/cvw3vx
title: msXL_322v_31_16.jpg
DOI: 10.25346/s6eecgix/2czz78
title: msXV_078r_22_70.jpg
DOI: 10.25346/s6eecgix/mmr1ds
title: msXV_078r_22_69.jpg
DOI: 10.25346/s6eecgix/fiybb8
title: msXV_078r_22_68.jpg
DOI: 10.25346/s6eecgix/qq1fst
title: msXV_078r_22_67.jpg
DOI: 10.25346/s6eecgix/qxfesr
title: msXV_078r_22_66.jpg
DOI: 10.25346/s6eecgix/w3limo
title: msXV_078r_22_65.jpg
DOI: 10.25346/s6eecgix/ww5ljt
title: msXV_078r_22_64.jpg
DOI: 10.25346/s6eecgix/guakye
title: msXV_078r_22_63.jpg
DOI: 10.25346/s6eecgix/8x3yjr
title: msXV_078r_22_62.jpg
DOI: 10.25346/s6eecgix/gttc0q
title: msXV_078r_22_61.jpg
DOI: 10.25346/s6eecgix/pm7v6f
title: msXV_078r_22_60.jpg
DOI: 10.25346/s6eecgix/ydsogu
title: msXV_078r_15_12.jpg
DOI: 10.25346/s6eecgix/nnw0bw
title: msXV_078r_15_11.jpg
DOI: 10.25346/s6eecgix/pslges
title: msXV_078r_15_10.jpg
DOI: 10.25346/s6eecgix/oalyse
title: msXV_078r_15_09.jpg
DOI: 10.25346/s6eecgix/ucjvrr
title: msXV_078r_15_08.jpg
DOI: 10.25346/s6eecgix/h3zifg
title: msXV_078r_15_07.jpg
DOI: 10.25346/s6eecgix/ah9vrq
title: msXV_078r_15_06.jpg
DOI: 10.25346/s6eecgix/gbttei
title: msXV_078r_15_05.jpg
DOI: 10.25346/s6eecgix/w6zlax
title: msXV_078r_15_04.jpg
DOI: 10.25346/s6eecgix/rq9epo
title: msXV_078r_15_03.jpg
DOI: 10.25346/s6eecgix/pkv5ec
title: msXV_078r_15_02.jpg
DOI: 10.25346/s6eecgix/urosoe
title: msXV_078r_15_01.jpg
DOI: 10.25346/s6eecgix/l8r77k
title: msXV_078r_0_ring.jpg
DOI: 10.25346/s6eecgix/vildgv
title: msXV_078r.jpg
DOI: 10.25346/s6eecgix/fydmmg
title: msXV_028v_65_61.tif
DOI: 10.25346/s6eecgix/vs2fw5
title: msXV_028v_65_60.tif
DOI: 10.26023/encb-8qwb-0012
title: ACCLIP: HIAPER Airborne Radiation Package (HARP) Actinic Flux Data. Version 1.0

description: Photolysis frequencies and actinic flux data from the HIAPER Airborne Radiation Package (HARP) that flew aboard the NSF/NCAR HIAPER GV aircraft for 14 research flights during the ACCLIP campaign. The flights were over the western Pacific Ocean.
DOI: 10.25346/s6eecgix/wbnoys
title: msXV_028v_65_59.tif
DOI: 10.25346/s6eecgix/aiwgc7
title: msXV_028v_65_58.tif
DOI: 10.25346/s6eecgix/gtq5cu
title: msXV_028v_65_57.tif
DOI: 10.25346/s6eecgix/nebn79
title: msXV_028v_65_56.tif
DOI: 10.25346/s6eecgix/h7bobv
title: msXV_028v_65_55.tif
DOI: 10.25346/s6eecgix/wowafz
title: msXV_028v_65_54.tif
DOI: 10.25346/s6eecgix/nztxdf
title: msXV_028v_65_53.tif
DOI: 10.25346/s6eecgix/7xkr3e
title: msXV_028v_65_52.tif
DOI: 10.25346/s6eecgix/xgcc9a
title: msXV_028v_65_51.tif
DOI: 10.25346/s6eecgix/6pjv7r
title: msXV_028v_65_50.tif
DOI: 10.25346/s6eecgix/syostc
title: msXV_028v_55_49.tif
DOI: 10.25346/s6eecgix/dd19cv
title: msXV_028v_55_48.tif
DOI: 10.25346/s6eecgix/vsgpv0
title: msXV_028v_55_47.tif
DOI: 10.25346/s6eecgix/wb71vw
title: msXV_028v_55_46.tif
DOI: 10.25346/s6eecgix/hqmxho
title: msXV_028v_55_45.tif
DOI: 10.25346/s6eecgix/mhxqbe
title: msXV_028v_55_44.tif
DOI: 10.25346/s6eecgix/lqxvwt
title: msXV_028v_55_43.tif
DOI: 10.25346/s6eecgix/3gdxrr
title: msXV_028v_55_42.tif
DOI: 10.25346/s6eecgix/rd4str
title: msXV_028v_55_41.tif
DOI: 10.25346/s6eecgix/1ogeey
title: msXV_028v_55_40.tif
DOI: 10.25346/s6eecgix/cxqqp1
title: msXV_028v_55_39.tif
DOI: 10.25346/s6eecgix/t1r3yn
title: msXV_028v_55_38.tif
DOI: 10.25346/s6eecgix/ev8wji
title: msXV_028v_46_37.tif
DOI: 10.25346/s6eecgix/imh7gn
title: msXV_028v_46_36.tif
DOI: 10.25346/s6eecgix/4yegbs
title: msXV_028v_46_35.tif
DOI: 10.25346/s6eecgix/jgtvxv
title: msXV_028v_46_34.tif
DOI: 10.25346/s6eecgix/px7kzx
title: msXV_028v_46_33.tif